Reported positive Phase 2a clinical data for CRx-191 in plaque psoriasis in which statistically significant reductions in psoriatic infiltrate thickness and erythema (redness) were observed as well as clinically significant improvements in clinical skin assessments. Based on this encouraging data, CombinatoRx has initiated conversations with prospective partners to secure resources focused on maximizing the potential of CRx-191, the first in a series of topical dermatology product candidates within the CombinatoRx portfolio. The increase is due primarily to costs associated with the clinical development of our drug candidates, including Phase 2b clinical trials for CRx-102 and a Phase 2a clinical trial of CRx-401. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its financial condition and results of operations, financial guidance for the fiscal year 2008, its product candidates, including CRx-191, and their clinical potential, its plans for clinical, preclinical and formulation development of its product candidates, its business development plans and its drug discovery technology. read more

Filed in: Cash Advance Type